

# Adaptive Designs and Multiple Testing Procedures (ADMTP) Workshop 2025

## Provisional Scientific Program

*Note: the program below is subject to speaker confirmation*

### Wednesday 26th February

<b>8.00 – 8.30</b>	<b>Registration and coffee</b>
<b>8.30 – 8.35</b>	<b>Welcome</b>
<b>8.35 – 10.40</b>	<b>Dose finding and dose selection</b> <ul style="list-style-type: none"><li>• Designing a seamless P1/P2a open enrollment CRM dose escalation study <i>Elias Laurin Meyer</i></li><li>• On the Consistency of Partial Ordering Continual Reassessment Method (POCRM) with Model and Ordering Misspecification <i>Weishi Chen</i></li><li>• Joint modelling of ctDNA and response in dose-finding designs in oncology <i>Xijin Chen</i></li><li>• Applying Bayesian Response Adaptive Randomization to dose-ranging platform trials <i>Connor Fitchett</i></li><li>• Optimizing Dose Selection Designs for Phase 3 Trials <i>Cornelia Kunz</i></li><li>• Adding an active dose level to an ongoing randomized controlled phase III study <i>Lorenz Uhlmann</i></li></ul>
<b>10.40 – 11.00</b>	<b>Coffee</b>
<b>11.00 – 12.45</b>	<b>Discussion session on the practical challenge</b> <ul style="list-style-type: none"><li>• Navigating Interim Analyses and Multiple Endpoints: Handling Accelerated Recruitment and Converging Analyses <i>Franz König</i></li><li>• Adjusting the information fraction by sample-size reassessment <i>Fredrik Öhrn</i></li><li>• Exploitation of multivariate central limit theorems in a closed test procedure for group sequential designs <i>Moritz Fabian Danzer</i></li><li>• Discussants (TBC)</li></ul>
<b>12.45 – 13.30</b>	<b>Lunch</b>

13.30 – 15.15	<p><b>Group sequential designs</b></p> <ul style="list-style-type: none"> <li>Group-sequential methods for generalised pairwise comparisons <i>Stephen Schüürhuis</i></li> <li>Two-Part Models in Group Sequential Designs for Zero-Inflated Data <i>Fabrice Lotola Mougani</i></li> <li>Using Machine Learning to Optimize Trial Design <i>Tom Parke</i></li> <li>Accounting for delayed responses in group sequential designs – needed or nice to have? <i>Carolyn Herrmann</i></li> <li>Evaluating the impact of outcome delay on adaptive designs <i>Aritra Mukherjee</i></li> </ul>
15.15 – 15.35	Coffee
15.35 – 17.40	<p><b>Platform trials</b></p> <ul style="list-style-type: none"> <li>Online control of the Family-wise error rate (FWER) for multi-arm multi-stage platform trials <i>Jiangyue Yao</i></li> <li>Adjusted treatment effect estimators for platform trials with interim analyses utilizing non-concurrent controls <i>Pavla Krotka</i></li> <li>Unconditional treatment effect estimates when adjusting for time in platform trials with binary endpoints <i>Marta Rofill Boig</i></li> <li>When is a multi-armed trial a platform trial and what are the implications? <i>Tobias Mielke</i></li> <li>Improving implementation of Adaptive Multi-Arm Multi-Stage Trials: The MAMS R Package <i>Nikita Mozgunov</i></li> <li>A Fair and Efficient Randomization Scheme for Multi-Arm Seamless Two-Phase Clinical Trials <i>Peter Jacko</i></li> </ul>

## Thursday 27th February

8.00 – 8.30	Registration and coffee
8.30 – 10.35	<p><b>Response-adaptive randomisation</b></p> <ul style="list-style-type: none"> <li>Maximizing Power of Statistical Tests in Clinical Trials <i>Lukas Pin</i></li> <li>Response Adaptive Randomization – when trying to select the best arm/dose from those being tested <i>Tom Parke</i></li> <li>Exact statistical analysis for response-adaptive clinical trials: A general and computationally tractable approach <i>Stef Baas</i></li> </ul>

	<ul style="list-style-type: none"> <li>• Patient-oriented response-adaptive designs based on a novel information measure in multi-arm trials with quantitative endpoints <i>Gianmarco Caruso</i></li> <li>• Covariate-Adjusted Response Adaptive Designs for Semiparametric Survival Models <i>Ayon Mukherjee</i></li> <li>• Design and inference for multi-arm clinical trials with informational borrowing: the interacting urns design <i>Rosamarie Frieri</i></li> </ul>
<b>10.35 – 11.05</b>	<b>Coffee + Working group meeting</b>
<b>11.05 – 12.50</b>	<b>Estimation</b> <ul style="list-style-type: none"> <li>• Covariate Adjustment in Bayesian Adaptive Randomized Controlled Trials <i>James Willard</i></li> <li>• Confidence intervals for adaptive designs <i>David Robertson</i></li> <li>• The uniformly most powerful conditional unbiased test and conditional confidence interval in two-stage adaptive enrichment designs <i>Enyu Li</i></li> <li>• Pre-specification and Bias in Hybrid RCTs <i>Han Chang Chiam</i></li> <li>• Exploratory Adaptive Enrichment Design with Sample Size Re-estimation: A Novel Approach for Clinical Trial Optimization <i>Elad Berkman</i></li> </ul>
<b>12.50 – 13.35</b>	<b>Lunch</b>
<b>13.35 – 15.20</b>	<b>Multiple testing</b> <ul style="list-style-type: none"> <li>• Adding baskets to an ongoing basket trial with information borrowing <i>Libby Daniells</i></li> <li>• Optimising graph-based multiple testing procedures by incorporating clinical considerations into flexible power objectives for FWER control <i>Alex Spiers</i></li> <li>• Optimizing Endpoint Analysis in the context of Kidney Transplant Studies: Composite vs. Multiplicity-Corrected Approaches <i>Felix Herkner</i></li> <li>• Extensions to a closed testing procedure for assessing efficacy in a prespecified subpopulation <i>Michael Grayling</i></li> <li>• Sequential conduct of clinical trials <i>Leonard Held</i></li> </ul>
<b>15.20 – 15.40</b>	<b>Coffee</b>
<b>15.40 – 17.25</b>	<b>Complex Innovative Designs and Decision Analysis</b> <ul style="list-style-type: none"> <li>• Real-world use of adaptive designs in paediatric clinical trials – A review of the European Medicines Agency’s Clinical Trials Information System (CTIS) <i>Fabian Eibensteiner</i></li> </ul>

	<ul style="list-style-type: none"> <li>• Bayesian decision analysis for clinical trial design with binary outcome in the context of Ebola Virus Disease outbreak – Simulation study <i>Drifa Belhadi</i></li> <li>• Communicating Complex Considerations in Dual Endpoint Trial Design – An Oncology Case Study <i>Boaz Adler</i></li> <li>• Assessing the Effects of Additional Investment in Earlier Phase Trials to Enhance Overall Program Probability of Success Through Informed Priors <i>Valeria Mazzanti</i></li> <li>• Model-Guided Parameter Optimization for Complex Innovative Trial Designs <i>Raviv Pryluk</i></li> </ul>
<b>17.25 – 17.30</b>	<b>Closing</b>